Mubalake Abudoureyimu
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Retraction Note: Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression.
Journal: Cell death & disease
Published: April 22, 2025
Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma.
Journal: International journal of immunopathology and pharmacology
Published: February 03, 2025
Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma.
Journal: Biochemical and biophysical research communications
Published: August 18, 2023
Correction to: Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression.
Journal: Cell death & disease
Published: December 24, 2021
Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma.
Journal: American journal of cancer research
Published: August 20, 2020
The role of Aurora-A in human cancers and future therapeutics.
Journal: American journal of cancer research
Published: July 08, 2020
Corrigendum: Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC.
Journal: Frontiers in oncology
Published: April 13, 2020
Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
Journal: Frontiers in oncology
Published: February 08, 2020
Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
Journal: Frontiers in oncology
Published: August 20, 2019
Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC.
Journal: Frontiers in oncology
Published: June 14, 2019
Last Updated: 09/26/2026